

***Fiscal Year 2023 Department of Defense Parkinson’s Research Program (PRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Early Investigator Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-PRP-EIRA</p>	<p>Investigator must be a postdoctoral or clinical fellow, instructor, or assistant professor within 10 years of advanced degree or residency training completion (or equivalent).</p>	<ul style="list-style-type: none"> • Supports research opportunities for investigators in the early stages of their careers, under the guidance of one or two designated Mentor(s). • The Early Investigator is considered the Principal Investigator (PI) of the application and must exhibit strong potential for, and commitment to, pursuing a career as an investigator at the forefront of PD research • Mentor(s) must have experience in PD research and mentoring as demonstrated by a record of active funding, recent publications, and successful mentorship. • Research must address at least one of the FY23 PRP Focus Areas. • Preliminary data are encouraged but not required. • Submission of a Letter of Intent is required prior to full application submission. • <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$500,000 for total costs (includes direct and indirect costs). • The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent [LOI]): July 27, 2023 5:00 p.m. Eastern time (ET)</p> <p>Confidential Letters of Recommendations: August 23, 2023 5:00 p.m. ET</p> <p>Application: August 17, 2023 11:59 p.m. ET</p>
<p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-PRP-IIRA</p>	<p>Independent investigators at or above the level of assistant professor (or equivalent).</p>	<ul style="list-style-type: none"> • Supports highly rigorous, multidisciplinary, high-impact research projects that have the potential to make an important contribution to Parkinson’s research. • This award mechanism supports the full spectrum of research from basic science through clinical research. • Research must address at least one of the FY23 PRP Focus Areas. • Preliminary data to support feasibility are encouraged but not required. • Submission of a Letter of Intent is required prior to full application submission. • <i>Clinical trials are allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1.5 million (M) for total costs (includes direct and indirect costs). • The maximum period of performance is 3 years. 	<p>LOI: July 27, 2023 5:00 p.m. ET</p> <p>Application: August 17, 2023 11:59 p.m. ET</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Synergistic Idea Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-PRP-SIA</p>	<p>Independent investigators at or above the level of assistant professor (or equivalent).</p>	<ul style="list-style-type: none"> • Supports new ideas that represent synergistic approaches to PD research involving two or four PIs. • Investigators should utilize their complementary and synergistic perspectives to address a central problem or question in Parkinson’s research. • This award is designed to support both new and pre-existing partnerships and encourages participation of PIs from other research fields. • Research must address at least one of the FY23 PRP Focus Areas. • Preliminary data to support feasibility are encouraged but not required. • Submission of a Letter of Intent is required prior to full application submission. • <i>Clinical trials are allowed.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$3.0M for total costs (includes direct and indirect costs). • The maximum period of performance is 4 years. 	<p>LOI: July 27, 2023 5:00 p.m. ET</p> <p>Application: August 17, 2023 11:59 p.m. ET</p>